Search results for "HOMA"

showing 10 items of 956 documents

Transmission of angioimmunoblastic T-cell lymphoma by bone marrow transplant

2014

Accidental transmission of lymphoma by bone marrow transplant is a rarely reported event [1–5], since candidates are only accepted for hematopoietic stem cell donation after a work-up that routinel...

Cancer ResearchAngioimmunoblastic T-cell lymphomaBone marrow transplantPathologymedicine.medical_specialtybusiness.industryTransmission (medicine)Hematopoietic stem cellHematologymedicine.diseaseLymphomamedicine.anatomical_structureOncologymedicinebusinessLeukemia & Lymphoma
researchProduct

SAKK 36/13 ‐ IBRUTINIB PLUS BORTEZOMIB AND IBRUTINIB MAINTENANCE FOR RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: FINAL REPORT OF A PHASE I/II TRIAL…

2021

Cancer ResearchBortezomibbusiness.industryHematologyGeneral Medicinechemistry.chemical_compoundPhase i iiOncologychemistryIbrutinibCancer researchmedicineRefractory Mantle Cell Lymphomabusinessmedicine.drugHematological Oncology
researchProduct

The effects of the macrocyclic lactone bryostatin-1 on leukemic cells in vitro.

1992

The macrocyclic lactone bryostatin-1 was found to exert in vitro antineoplastic activity against several leukemic cell lines, including human K562 erythroleukemia, HL60 promyelocytic leukemia, REH and MOLT-4 lymphoblastic leukemias, CCRFCEM lymphoma, KG-1 myeloid leukemia, and murine P388 lymphocytic leukemia. No statistically significant difference in sensitivity to bryostatin-1 was found between adriamycin-resistant P388 and K526 subclones and their sensitive counterparts. Freshly explanted clonogenic leukemic cells showed a variable sensitivity to bryostatin-1 in 10/12 tested samples. The IC50 of clonogenic leukemic cells was 4 × 10–3 M bryostatin-1, and that of normal marrow CFU-GM was…

Cancer ResearchBryostatin 1LymphomaHL60Antineoplastic AgentsAntileukemic agent030218 nuclear medicine & medical imaging03 medical and health scienceschemistry.chemical_compoundLactones0302 clinical medicinehemic and lymphatic diseasesmedicineTumor Cells CulturedHumansClonogenic assayTumor Stem Cell AssayLeukemiaChemistryMyeloid leukemiaGeneral Medicinemedicine.diseaseBryostatinsHaematopoiesisLeukemiaOncology030220 oncology & carcinogenesisCancer researchMacrolidesDrug Screening Assays AntitumorK562 cellsTumori
researchProduct

Abstract 4107: Targeted re-sequencing of neuroblastoma tumors reveals chromosomal rearrangements that involve the Anaplastic Lymphoma Kinase (ALK) ge…

2013

Abstract Neuroblastoma (NBL) is a cancer of early childhood arising from the developing sympathetic nervous system. NBL tumors display a broad clinical and biological heterogeneity, ranging from highly aggressive tumors with fatal outcome to tumors with spontaneous regression. Recurrent mutations are mainly only observed in Anaplastic Lymphoma Kinase (ALK), which is involved in the pathogenesis of both familiar and sporadic NBL. ALK encodes a tyrosine kinase receptor with importance in neuronal development and was initially characterized in anaplastic large cell lymphoma from a translocation leading to the NPM-ALK fusion protein. Subsequent studies show that additional ALK chimeras have bee…

Cancer ResearchChromosomal translocationBiologyAmpliconmedicine.diseaseFusion proteinMolecular biologyExonOncologyhemic and lymphatic diseasesNeuroblastomamedicineAnaplastic lymphoma kinaseKinase activityAnaplastic large-cell lymphomaCancer Research
researchProduct

From a Better Understanding of the Mechanisms of Action of Histone Deacetylases Inhibitors to the Progress of the Treatment of Malignant Lymphomas an…

2017

Background Notable progress has been made in chemo- and immunotherapy of B-cell lymphomas, but less in the treatment of T-cell lymphomas. Objective Histone deacetylases inhibitors are a potentially useful therapeutic mean, as an epigenetic dysregulation is present in lymphomas, and especially in T-cell types. We aimed to study the progress made in this area. Method A mini-review was achieved using the articles published in PubMed in the last two years and the new patents made in this field. Results Histone deacetylases inhibitors are involved in the derepression of tumor suppressor genes through a histone deacetylase-mediated transcriptional process. Their inhibition is followed by cell cyc…

Cancer ResearchDrug exportmedicine.medical_treatmentCellular differentiationAntineoplastic Agents010402 general chemistryLymphoma T-Cell01 natural sciencesHistone DeacetylasesRomidepsinPatents as TopicDrug DiscoveryPlasma Cell MyelomamedicineAnimalsHumansPharmacology (medical)Epigeneticsbiology010405 organic chemistrybusiness.industryDrug SynergismGeneral MedicineImmunotherapymedicine.diseasePeripheral T-cell lymphoma0104 chemical sciencesHistone Deacetylase InhibitorsHistoneOncologyDrug DesignImmunologyCancer researchbiology.proteinbusinessMultiple Myelomamedicine.drugRecent patents on anti-cancer drug discovery
researchProduct

Apoptotic induction in transformed follicular lymphoma cells by Bcl-2 downregulation.

1998

The roles of Bcl-2 protein and the protein ratio of Bcl-2/Bax in regulating cell growth in various lymphoma cell lines were examined. A dose-dependent decrease in Bcl-2 protein expression was observed in the different lymphomas incubated with lipid-incorporated bcl-2 antisense oligonucleotides (L-bcl-2). Growth inhibition was observed in a transformed follicular lymphoma (FL) cell line, which has the t(14;18) translocation and Bcl-2 protein overexpression. One of the mechanisms by which L-bcl-2 growth inhibition is mediated in these transformed FL cells might be through apoptotic induction, because the treated cells had an increased apoptotic index and showed the typical DNA fragmentation. …

Cancer ResearchFollicular lymphomaDown-RegulationApoptosisBiologychemistry.chemical_compoundDownregulation and upregulationProto-Oncogene ProteinsmedicineTumor Cells CulturedHumansLymphoma Follicularbcl-2-Associated X ProteinDrug CarriersCell growthHematologyOligonucleotides Antisensemedicine.diseaseLymphomaGene Expression Regulation NeoplasticCell Transformation NeoplasticOncologychemistryProto-Oncogene Proteins c-bcl-2ApoptosisCell cultureLiposomesCancer researchDNA fragmentationGrowth inhibitionCell DivisionLeukemialymphoma
researchProduct

Challenges and new prospects in hepatosplenic γδ T-cell lymphoma.

2014

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoid neoplasms characterized by aggressive clinical behavior and dismal prognosis. Hepatosplenic γδ T-cell lymphoma (γδ-HSTL) is a particular form of PTCL that arises from a small subset of γ/δ T-cell receptor-expressing lymphocytes. γδ-HSTL has a rapidly progressive course and poor outcome due also to its refractoriness to conventional chemotherapy regimens. The very low incidence of γδ-HSTL, along with its propensity to mimic different pathological entities, makes this lymphoma a true diagnostic challenge. In this review, we highlight the biological and clinical features of γδ-HSTL that contribute to making this lymphoma…

Cancer ResearchHepatosplenic T-cell lymphomaSpleenDiseaseBiologyT cell lymphomaAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansT-cell lymphomaPathologicalgamma delta T cell lymphomahepatosplenic T cell lymphomaSplenic NeoplasmsLiver NeoplasmsLymphoma T-Cell PeripheralReceptors Antigen T-Cell gamma-deltaHematologymedicine.diseaseCombined Modality Therapyperipheral T cell lymphomasLymphomaT cell lymphoma; gamma delta T cell lymphomas; hepatosplenic T cell lymphoma; peripheral T cell lymphomasTreatment Outcomemedicine.anatomical_structureOncologyImmunologyConventional chemotherapyBone marrowStem Cell Transplantation
researchProduct

Immune Therapy of Lympho-Hemopoietic Malignancies.

2017

Cancer ResearchImmunoconjugatesbusiness.industryAntibodies MonoclonalHematologyPrecursor Cell Lymphoblastic Leukemia-LymphomaImmune therapy03 medical and health sciencesHaematopoiesis0302 clinical medicineTreatment OutcomeOncologyLeukemia Myeloid030220 oncology & carcinogenesisHematologic NeoplasmsImmunologyAcute DiseaseMedicineHumans030212 general & internal medicineImmunotherapybusinessOncology research and treatment
researchProduct

Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-dependent adhesion to fibronectin and VCAM-1 on bone marrow hematopoietic proge…

2001

Stromal cell-derived factor-1alpha (SDF-1alpha) is a potent chemoattractant for hematopoietic progenitor cells (HPC), suggesting that it could play an important role during their migration within or to the bone marrow (BM). The integrin VLA-4 mediates HPC adhesion to BM stroma by interacting with CS-1/fibronectin and VCAM-1. It is required during hematopoiesis and homing of HPC to the BM. As HPC migration in response to SDF-1alpha might require dynamic regulation of integrin function, we investigated if SDF-1alpha could modulate VLA-4 function on BM CD34(hi) cells.CD34(hi) BM cells and hematopoietic cell lines were tested for the effect of SDF-1alpha on VLA-4-dependent adhesion to CS-1/fibr…

Cancer ResearchIntegrinsReceptors CXCR4Stromal cellIntegrinCD34Receptors Lymphocyte HomingVascular Cell Adhesion Molecule-1Bone Marrow CellsIntegrin alpha4beta1Hematopoietic Cell Growth FactorsCell LineColony-Forming Units Assaychemistry.chemical_compoundMiceLeukemia Megakaryoblastic AcutePrecursor B-Cell Lymphoblastic Leukemia-LymphomaGeneticsCell AdhesionTumor Cells CulturedAnimalsHumansVCAM-1Cell adhesionMolecular BiologybiologyChemotaxisVLA-4Antibodies MonoclonalCell BiologyHematologyHematopoietic Stem CellsChemokine CXCL12Peptide FragmentsRecombinant ProteinsCell biologyFibronectinsFibronectinchemistryLiverbiology.proteinStromal CellsChemokines CXCHoming (hematopoietic)Signal TransductionExperimental hematology
researchProduct

The BCL6 gene in B-cell lymphomas with 3q27 translocations is expressed mainly from the rearranged allele irrespective of the partner gene

2003

The BCL6 gene, which functions as a transcription repressor, is the target of multiple chromosomal translocations in non-Hodgkin's lymphomas (NHL). These translocations occur in the nontranslated region of the BCL6 gene, juxtaposing regulatory sequences of the diverse partner genes to the open reading frame of the BCL6 gene and thus are thought to deregulate BCL6 gene expression. The levels of expression of the BCL6 gene and protein have been demonstrated to predict the clinical outcome of diffuse large B-cell lymphomas. By contrast, the prognostic significance of BCL6 gene translocations is unclear. In this study we have sought an explanation for this apparent discrepancy. We examined tumo…

Cancer ResearchLymphoma B-CellBiologyTranslocation Geneticimmune system diseasesProto-Oncogene Proteinshemic and lymphatic diseasesGene expressionTumor Cells CulturedHumansRNA MessengerAllelePromoter Regions GeneticGeneAllelesGene RearrangementGeneticsRegulation of gene expressionPromoterHematologyGene rearrangementBCL6Neoplasm ProteinsDNA-Binding ProteinsGene Expression Regulation NeoplasticRepressor ProteinsOncologyRegulatory sequenceMutationProto-Oncogene Proteins c-bcl-6Cancer researchChromosomes Human Pair 3Transcription FactorsLeukemia
researchProduct